slide1
Download
Skip this Video
Download Presentation
Instructions received from Program C hair A. Gronchi

Loading in 2 Seconds...

play fullscreen
1 / 35

Instructions received from Program C hair A. Gronchi - PowerPoint PPT Presentation


  • 67 Views
  • Uploaded on

Discussion of papers 3-4 and posters D-H, Session 1, CTOS, Prague, November 2012 Patrick Schöffski, Leuven, Belgium. Instructions received from Program C hair A. Gronchi. “... to discuss how presented data are going to change the landscape of sarcoma management today or tomorrow… ”.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Instructions received from Program C hair A. Gronchi' - lucio


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Discussion of papers 3-4 and posters D-H, Session 1, CTOS, Prague, November 2012Patrick Schöffski, Leuven, Belgium

instructions received from program c hair a gronchi
Instructions received from Program Chair A. Gronchi
  • “...to discuss how presented data are going to change the landscape of sarcoma management today or tomorrow…”
slide4

ID 1436983, paper #3, p. 66Simultaneous autophagy induction and inhibition induces cell death through necroptosis in sarcomas that lack argininosuccinate synthetase 1 expressionPhilip A. Boone et al., St. Louis, USA

slide5

Conflict of interest of discussant:

    • None
  • Drug(s) tested:
    • Pegylated arginine delminase, an inhibitor of argininosuccinate synthase 1 (ASS 1), which is a key enzyme in the urea cycle
  • Experimental concept:
    • Study involving tissue samples, cell lines and xenografts using immunohistochemistry, assays for cell proliferation and cell death
  • Study aim(s):
    • To study the potential role of inhibition of ASS 1 in sarcoma models
    • Absence of ASS 1 associated with poor outcome in certain sarcomas
  • Key results:
    • ASS 1 not expressed in 85 % of sarcomas: promising
    • Arginine depletion by pegylated arginine delminase arrests cell cycle
    • Simultaneous autophagy induction and inhibition by chloroquin induces cell death through necroptosis in enzyme-negative sarcomas
  • Conclusions of authors:
    • Arginine depletion using pegylated arginine delminase may control tumor burden in sarcomas lacking ASS 1
implications for the sarcoma community
Implications for the sarcoma community
  • New concept in sarcoma oncology: focusing on an absent molecular target
  • Clinical exploration of arginine depletion with pegylated arginine delminase +/- chloroquine (or related compounds that can be used in the clinic) warranted
  • Would suggest Phase 1 dose finding followed by disease-specific trial in ASS 1-negative bone and soft tissue sarcomas
slide8

ID 1408457 , paper #4, p. 66 Y box binding protein 1 (YB-1): a novel hypoxic response integrated factor steering sarcoma cell invasion & metastatic disseminationAmal Mohammad El-Naggar et al., Vancouver, Canada

slide9

Drug(s) tested:

    • None
  • Experimental concept:
    • Extensive preclinical study involving in vitro work, nude mice, zebrafish, genetically modified cells and various assays exploring cell motility and metastasis-promoting capacity of YB-1
  • Study aim(s):
    • To assess the potential role of YB-1 in sarcomas
    • YB-1 is a multifunctional cellular protein that mediates malignant transformation, cell migration and drug resistance, and is involved in epithelial-to-mesenchymal transition (EMT)
    • Key results:
    • YB-1 found to contribute to sarcoma cell motility (likely through its downstream mediator HIF1a), invasion and metastasis
  • Conclusions of authors:
    • YB-1 is a potential target for the treatment of metastatic sarcomas
proposed mechanism for the interaction between yb 1 and hif1a
Proposed mechanism for the interaction between YB-1 and HIF1a

HIF1α Translation

VEGF & neovascularization

YB-1

Hypoxic Induction

(Cap-independent Mechanism?)

Tumor Progression

Metastatic Dissemination of sarcoma cells

implications for the sarcoma community1
Implications for the sarcoma community
  • No immediate implications as it is unclear whether YB-1 is druggable with specific agents
  • Methodological challenge: clinical trial designs to assess anti-migratory or anti-metastatic capacity of new treatments are far from being optimal
slide12

ID 1436950, poster H, p. 69Trabectedin and PARP-1 inhibitors combination in preclinical models of bone and soft tissue sarcomaYmera Pignochino et al., Torino, Italy

slide13

Drug(s) tested:

    • Trabectedin, a DNA-minor groove binder
    • Olaparib and veliparib as PARP inhibitors
  • Experimental concept:
    • Preclinical study using cell lines of soft tissue and bone sarcomas, exploring the interaction between trabectedin and two PARP inhibitors
  • Study aim(s):
    • To demonstrate in vitro-synergism between the minor groove binder and olaparib/veliparib
  • Key results:
    • Trabectedin induces strong activation of PARP1 enzymatic activity in sarcoma cell lines
    • PARP1-inhibitors potentiate DNA damage induced by trabectedin
  • Conclusions of authors:
    • Trabectedinand PARP-inhibitors show synergistic anti-proliferative effects in sarcoma cell lines, with induction of cell cycle arrest and apoptosis
implications for the sarcoma community2
Implications for the sarcoma community
  • Would suggest a disease-specific Phase 1 study of trabectecin + PARP inhibitor (e.g. in sarcomas, breast cancer and ovarian cancer), involving sequential biopsies
  • Window-of-opportunity trial, e.g. in myxoid/ roundcell liposarcoma prior to surgery, with extensive pharmacodynamic tissue sampling
  • Bottleneck: availability of PARP-inhibitors
slide17

ID 1437492 , poster D, p. 67A phase II trial of novel anthracycline amrubicin in patients with advanced soft tissue sarcomaLaunce G. Gouw et al., Salt Lake City, USA

slide18

Drug(s) tested:

    • Amrubicin
  • Experimental concept:
    • Ongoing single-arm, open label Phase 2 trial in treatment-naive soft tissue sarcoma
  • Study aim(s):
    • Clinical: to study RR, PFS, safety and toxicity, OS
    • Translational: genomic and proteomic biomarkers
  • Key results:
    • AEs similar to experience with drug in other indications
    • No cardiotoxicity, no hematological toxicity
    • PR 25%, SD 58%, CBR 83%
    • Conclusions of authors:
    • Well-tolerated and encouraging activity in sarcoma
    • Further studies warranted as single-agent or in combination
implications for the sarcoma community3
Implications for the sarcoma community
  • Randomized trial(s) required to assess the added value of this anthracyclin as compared to established treatment standard doxorubicin
  • Drug competes with a number of other innovative anthracyclin derivatives (non-cardiotoxic, tumor-activated, temperature-activated prodrugs...)
  • Non-inferiority trial comparing with doxorubicin will unlikely satisfy regulatory agencies and will not be the most attractive design for investigators
  • Drug qualifies for combination trials given its good safety profile, e.g. Phase 1 combo with palifosfamide
the benchmark eortc trial 62012
The benchmark: EORTC trial 62012

Overall survival (primary endpoint)

Response rate:

Doxorubicin 13.6 %

Progression-free survival:

Doxorubicin 4.6 mo

(95% CI 2.9 – 5.6)

Overall survival:

Doxorubicin 12.8 mo

(95.5 CI 10.5-14.3)

Survival at 1-year:

Doxorubicin 51 %

(95.5% CI 44-58)

HR = 0.83

(95.5% CI 0.67 – 1.03)

p = 0.076

Progression-free survival

HR = 0.74

(95% CI 0.60 – 0.90)

p = 0.003

Judson, Verweij, Gelderblom, Hartmann , Schöffski , Blay, deiTos, Marreaud , Litiere, van der Graaf, ESMO Vienna 2012

slide22

ID 1426644, poster G, p. 69Aldoxorubicin (INNO-206) is an active drug for the treatment of relapsed or refractory soft tissue sarcomasSant Chawla et al., Los Angeles, USA

slide23

Drug(s) tested:

    • Aldoxorubicin (INNO-206) is a prodrug of doxorubicin that binds to albumin through a specific linker
    • Active compound released due to the acidic environment of the tumor
  • Experimental concept:
    • Ongoing Phase 2 trial in sarcoma patients who failed prior chemo
    • Safety and efficacy of aldoxorubicin 350 mg/m2 (260 mg/m2 doxorubicin-equivalent) as single agent given i.v. q3w for up to 8 cycles
  • Study aim(s):
    • To explore the safety and efficacy of aldoxorubicin in previously treated sarcoma patients
  • Key results:
    • No relevant cardiotoxicity in patients exposed to high cumulative doses
    • Febrile neutropenia, sepsis and mucositis as SAEs
  • Conclusions of authors:
    • High cumulative doses can be administered even in anthracyclin-pretreated patients, with evidence of antitumor efficacy
implications for the sarcoma community4
Implications for the sarcoma community
  • Randomized trial(s) required to assess the value of this anthracyclin as compared to doxorubicin in first line
  • Alternative strategy to explore the drug in patients progressing after previous response to doxorubicin
  • Drug competes with other innovative anthracyclin derivatives in the first line setting, and regulators will likely require more than a non-inferiority trial
  • In second line it would compete with trabectedin, pazopanib and a number of off label-treatments
  • Dose finding trial combining aldoxorubicin with palifosfamide to be considered as a strategic option
slide26

ID 1435530, poster E, p. 67TH-302 maintenance following TH-302 + doxorubicine induction: the results of a phase 2 studyKristen N. Ganjoo et al., Stanford, USA

slide27

Drug(s) tested:

    • Doxorubicin + TH-302, a prodrug of the DNA-crosslinking alkylator bromo-isophosphoramide mustard, that releases the active moeity under hypoxic conditions
  • Experimental concept:
    • Analysis of 48 patients who continued with maintenance TH-302 after having received up to 6 cycles of doxorubicin
  • Study aim(s)
    • To explore the role of TH-302 maintenance
  • Key results:
    • 53 % of patients entered maintenance period of Phase 2 trial after achieving CR, PR, SD, receiving TH-302 doses ranging between 300-167 mg days 1+8 q3w
    • 5 SDs converted to PR, 1 PR converted to CR during maintenance
  • Conclusions of authors:
    • Maintenance with TH-302 is well tolerated with limited hematological and manageable skin/mucosal toxicity; no cumulative toxicity during maintenance
implications for the sarcoma community5
Implications for the sarcoma community
  • Supportive evidence for ongoing TH-CR-406/ SARC021 Phase 3 study comparing doxorubicin with doxorubicin/TH-302, which involves TH-302 maintenance (primary endpoint: overall survival)
  • Ongoing trial is performed in an increasingly competitive trial environment
    • EORTC 62012 comparing doxorubicin with doxorubicin/ifosfamide failed to meet OS endpoint
    • Phase 3 with doxorubicin vs. doxorubicin/palifosfamide already completed accrual (primary endpoint: PFS)
slide30

ID 1426542, poster F, p. 68Phase I trial of abexinostat and doxorubicine in patients with metastatic sarcomaEdwin Choy et al., Boston, USA

slide31

Drug(s) tested:

    • Doxorubicin and abexinostat (PCI-24781), a HDAC inhibitor with preclinical activity in sarcoma cell lines and xenografts
  • Experimental concept:
    • Phase 1b dose finding study of abexinostat combined with doxorubicin
  • Study aim(s):
    • To identify MTD, safety, tolerability, PK and PD of abexinostat when administered on days 1-5 with doxorubicin 75 mg/m2 on day 4 q3w (+/- G-CSF ) in patients with advanced sarcoma
  • Key results:
    • DLTs included grade 3 and 4 neuropenia without G-CSF grade 3 infection and grade 4 thrombocytopenia with G-CSF
    • In 17 participants evaluable for response there was 1 PR and 12 SD, and 7 patients continued >=5 cycles
  • Conclusions of authors:
    • Abexinostatcan be safely combined with full dose doxorubicin, toxicity is manageable with G-CSF support, clinical benefit seen
implications for the sarcoma community6
Implications for the sarcoma community
  • Drug combination could be explored in a randomized Phase 2 study, with doxorubicin as the standard arm, involving maintenance with the HDAC inhibitor
  • Is the evidence for HDAC inhibition in sarcoma strong enough to embark on large, expensive trials?
  • If Phase 2 would generate a convincing efficacy signal the consecutive registration trial would have to be performed in an increasingly competitive environment
    • Outcome of Phase 3 with doxorubicin vs. doxorubicin/ palifosfamide likely reported at that point
    • Phase 3 trial doxorubicin vs. doxorubicin/Th-302 likely completed accrual at that point
please show your real excitement for all the good work presented in session 1
Please show your real excitement for all the good work presented in Session 1 

Hypnosis conference

ad